Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rani Therapeutics Holdings (RANI) Revenue (2020 - 2025)

Rani Therapeutics Holdings has reported Revenue over the past 5 years, most recently at $1.5 million for Q4 2025.

  • Quarterly results put Revenue at $1.5 million for Q4 2025, up 42.12% from a year ago — trailing twelve months through Dec 2025 was $1.6 million (up 58.85% YoY), and the annual figure for FY2025 was $1.6 million, up 58.85%.
  • Revenue for Q4 2025 was $1.5 million at Rani Therapeutics Holdings, up from $172000.0 in the prior quarter.
  • Over the last five years, Revenue for RANI hit a ceiling of $2.0 million in Q2 2021 and a floor of -$1.3 million in Q3 2023.
  • Median Revenue over the past 4 years was $172000.0 (2025), compared with a mean of $32555.6.
  • Biggest five-year swings in Revenue: skyrocketed 3168.33% in 2021 and later soared 42.12% in 2025.
  • Rani Therapeutics Holdings' Revenue stood at $2.0 million in 2021, then crashed by 166.09% to -$1.3 million in 2023, then skyrocketed by 179.32% to $1.0 million in 2024, then soared by 42.12% to $1.5 million in 2025.
  • The last three reported values for Revenue were $1.5 million (Q4 2025), $172000.0 (Q1 2025), and $1.0 million (Q4 2024) per Business Quant data.